Ethnic, gender, and age-related differences in the treatment of dyslipidemia

Area of Science:

• Cardiology
• Public Health
• Pharmacotherapy

Background:

• Coronary heart disease (CHD) is the leading cause of death in the US, with significant disparities observed across age, gender, and race/ethnicity.
• Older individuals (≥65 years) account for over 80% of CHD mortality.
• Women experience myocardial infarction (MI) later in life than men, leading to higher MI mortality rates. Significant racial disparities exist, with higher CHD death rates among Black individuals compared to White individuals, particularly for premature CHD.

Purpose of the Study:

• To explore the evidence supporting statin therapy for cardiovascular risk reduction.
• To address the underrepresentation of older adults, women, and ethnic minorities in clinical trials for lipid-lowering therapies.
• To advocate for aggressive treatment of CHD risk factors in high-risk populations.

Main Methods:

• Review of existing randomized, controlled clinical trial data on lipid-lowering therapy.
• Analysis of epidemiological data on CHD prevalence and mortality across different demographic groups.
• Exploration of evidence for statin efficacy in specific populations.

Main Results:

• Lipid-lowering therapy, specifically statins, has proven efficacy in preventing CHD events.
• Despite high CHD prevalence, older adults, women, and ethnic minorities have been historically underrepresented in clinical trials.
• Aggressive management of CHD risk factors is crucial for these demographic groups.

Conclusions:

• Statin therapy should be considered a key component of risk reduction strategies for older individuals, women, and ethnic minorities.
• Addressing disparities in clinical trial participation is essential for evidence-based cardiovascular care.
• Targeted interventions are necessary to mitigate the disproportionate burden of CHD in vulnerable populations.